Loading...
Loading...
DTIL| Name | Value |
|---|---|
| Revenues | 13.1M |
| Cost of Revenue | 2.0M |
| Gross Profit | 11.1M |
| Operating Expense | 25.5M |
| Operating I/L | -12.4M |
| Other Income/Expense | 0.3M |
| Interest Income | 1.9M |
| Pretax | -12.1M |
| Income Tax Expense | -5.3M |
| Net Income/Loss | -8.1M |
Precision BioSciences, Inc. is a clinical stage gene editing company in the United States. It specializes in developing in vivo gene editing and ex vivo allogeneic CAR T therapies. The company's ARCUS platform is designed to cure genetic disorders, and it offers various therapies such as PBCAR0191, PBCAR19B, and PBCAR269A targeting different types of cancers. Precision BioSciences also has development and commercial license agreements with partners to expand its allogeneic CAR T therapy offerings. Its revenue is generated through the development, licensing, and commercialization of gene editing and immunotherapy products.
